Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Memantine - Children's Medical Center Corporation/Merz Pharma

Drug Profile

Memantine - Children's Medical Center Corporation/Merz Pharma

Alternative Names: Akatinol; Axura; D-145; Ebixa; Extended-release memantine capsules - AbbVie; Memantine hydrochloride; Memary; Namenda; Namenda XR; SUN Y7017; SUNY 017

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Childrens Medical Center Corporation
  • Developer AbbVie; Allergan; Daiichi Sankyo Company; Forest Laboratories; Lundbeck A/S; Merz Pharma; Neurobiological Technologies; University of California, Davis
  • Class Amines; Analgesics; Antidementias; Antiglaucomas; Antiparkinsonians; Antispastics; Antitussives; Eye disorder therapies; Nitrates; Nootropics; Organic bridged compounds; Small molecules; Vascular disorder therapies
  • Mechanism of Action Nicotinic receptor antagonists; NMDA receptor antagonists; Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease; Cognition disorders; Dementia
  • Phase III Vascular dementia
  • Discontinued Asperger syndrome; Autistic disorder; Diabetic neuropathies; Fragile X tremor ataxia syndrome; Glaucoma; Neuropathic pain

Most Recent Events

  • 01 Jun 2022 Merz Pharmaceuticals completes its phase III clinical trials in Vascular dementia in Russia (PO) (NCT03986424)
  • 26 Apr 2022 Phase III development for Vascular dementia is still ongoing in Russia (PO) (NDR batch 22)
  • 22 Apr 2022 Merz Pharma completes enrolment in a phase III clinical trials in Vascular dementia in Russia (PO) (NCT03986424)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top